Mostrar el registro sencillo del ítem

dc.contributor.authorLABANDEIRA GUERRA, CARMEN MARIA 
dc.contributor.authorALONSO LOSADA, MARIA GEMA 
dc.contributor.authorYañez Baña, Rosa María 
dc.contributor.authorCimas Hernando, M. I.
dc.contributor.authorCabo López, Iria 
dc.contributor.authorPaz González, José Manuel 
dc.contributor.authorGonzalez Palmás, María José
dc.contributor.authorMartínez Miró, Cristina
dc.contributor.authorSantos García, Diego 
dc.date.accessioned2024-01-02T10:03:14Z
dc.date.available2024-01-02T10:03:14Z
dc.date.issued2021
dc.identifier.issn0741-238X
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/34523075es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/18476
dc.description.abstractINTRODUCTION: Mood disorders are frequent in Parkinson's disease (PD) and a favorable effect of safinamide on mood has been observed. We aimed to analyze the effectiveness of safinamide on mood as a secondary objective from the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on NON-MOTOR symptoms in patients with Parkinson's disease) study. METHODS: SAFINONMOTOR is a prospective open-label single-arm study conducted in five centers from Spain. Patients with PD were required to have at baseline a Non-Motor Symptoms Scale (NMSS) total score of at least 40. In this analysis, the changes from V1 (baseline) to V4 (6 months +/- 1 month) in the BDI-II (Beck Depression Inventory-II), NMSS mood/apathy domain, and PDQ-39 (Parkinson's Disease Questionnaire-39) emotional well-being domain were analyzed. Depression was identified and classified (DSM-IV and Judd criteria) at baseline and at the end of follow-up as major depression (MD), minor depression (mD), subthreshold depression (subD), and non-depression (nonD). RESULTS: Fifty patients with PD were included (age 68.5 +/- 9.12 years; 58% women; 6.4 +/- 5.1 years from diagnosis) and 44 patients (88%) completed the follow-up at 6 months. The BDI-II total score was reduced by 35.9% (from 15.88 +/- 10.46 at V1 to 10.18 +/- 6.76 at V4; p < 0.0001). A significant decrease in the NMSS mood/apathy domain and PDQ-39 emotional well-being domain was observed as well (p < 0.0001). At baseline, 52% of the patients presented MD, 34% mD, 12% subD, and 2% nonD whereas at V4 the percentages were 31.8%, 34.1%, 22.7%, and 11.4%, respectively (p = 0.029). CONCLUSIONS: Safinamide improves mood in patients with PD at 6 months.
dc.language.isoen
dc.rightsAtribución-NoComercial 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.titleEffectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
dc.typeJournal Articlees
dc.authorsophosLabandeira, C. M.;Alonso Losada, M. G.;Yáñez Baña, R.;Cimas Hernando, M. I.;Cabo López, I.;Paz González, J. M.;Gonzalez Palmás, M. J.;Martínez Miró, C.;Santos García, D.
dc.identifier.doi10.1007/s12325-021-01873-w
dc.identifier.pmid34523075
dc.identifier.sophos43242
dc.issue.number10
dc.journal.titleADVANCES IN THERAPY
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.)::Área Sanitaria de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.)::Área Sanitaria de A Coruña - Complexo Hospitalario Universitario de A Coruña::Neuroloxía
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.)::Área Sanitaria de Ourense, Verín e O Barco de Valdeorras::Complexo Hospitalario Universitario de Ourense::Neuroloxía
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.)::Área Sanitaria de Vigo - Complexo Hospitalario Universitario de Vigo::Neuroloxía
dc.page.initial5411
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUOes
dc.subject.keywordCHUACes
dc.subject.keywordCHUVIes
dc.subject.keywordCHUP
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number38


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial 4.0 Internacional